AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32841261 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1041
Study 34164846 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Chocolate (MC)
Number of subjects: 19
Study 34164846 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Chocolate (EC)
Number of subjects: 19
Study 34164846 — intervention group
Group type: COMPARATOR
Intervention: No Chocolate (N)
Number of subjects: 19
Study 32525235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy Continuation (MBCT-C) for 26 weeks
Number of subjects: 27
Study 32525235 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (Control)
Number of subjects: 27
Study 35416999 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 113
Study 35416999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 32108029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD) - instructed to eat <20 g/carbs/day
Number of subjects: 60
Study 32108029 — intervention group
Group type: COMPARATOR
Intervention: Control - instructed to avoid dietary changes
Number of subjects: 60
Study 32108029 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc exploratory analysis of LCD
Number of subjects: 60
Study 35984519 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular infiltration (PI)
Number of subjects: 44
Study 35984519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate 1E
Number of subjects: 0
Study 32965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate 26E
Number of subjects: 0
Study 32965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate 14E
Number of subjects: 0
Study 32965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate 7E
Number of subjects: 0
Study 32965526 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolate 19E
Number of subjects: 0
Study 32965526 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35382858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito Shield™, a spatial repellent incorporating transfluthrin
Number of subjects: 6120
Study 35382858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6120
Study 33969558 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interpersonal psychotherapy (IPT)
Number of subjects: 24
Study 35685524 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 108
Study 35685524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 34341395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based telephone follow-up
Number of subjects: 1890
Study 34341395 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1890
Study 32293810 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT with 100 µA (Group A)
Number of subjects: 56
Study 32293810 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT with 25 µA (Group B)
Number of subjects: 56
Study 32293810 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Group C)
Number of subjects: 56
Study 32293810 — intervention group
Group type: COMPARATOR
Intervention: Control group without intervention (Group D)
Number of subjects: 56
Study 36152329 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPS device
Number of subjects: 249
Study 36152329 — intervention group
Group type: COMPARATOR
Intervention: TLIF
Number of subjects: 249
Study 33682146 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal nursing intervention (AMACOMPRI)
Number of subjects: 66
Study 33682146 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 34779087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 190
Study 34779087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 34779087 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Metformin
Number of subjects: 190
Study 34424919 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver body mass index (BMI)
Number of subjects: 85
Study 34424919 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment scores
Number of subjects: 85
Study 34424919 — intervention group
Group type: EXPERIMENTAL
Intervention: Child nutritional status based on WAZ
Number of subjects: 85
Study 34978374 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily for 3 months
Number of subjects: 40
Study 34978374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32780605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel Noninvasive Ventilation (NIV)
Number of subjects: 40
Study 32780605 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 40
Study 33559343 — intervention group
Group type: EXPERIMENTAL
Intervention: nanocurcumin
Number of subjects: 54
Study 33559343 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 32586293 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention group
Number of subjects: 495
Study 32586293 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended intervention group combining web-based components with face-to-face workshops and posters
Number of subjects: 495
Study 32586293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 495
Study 36416118 — intervention group
Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232)
Number of subjects: 0
Study 36416118 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0
Study 34179755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine trigger point injection
Number of subjects: 80
Study 34179755 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline interfascial injection
Number of subjects: 80
Study 34179755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 32599445 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Depression (CD)
Number of subjects: 1013
Study 32599445 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression with Multiple Episodes (ME)
Number of subjects: 1013
Study 32599445 — intervention group
Group type: COMPARATOR
Intervention: Depression with Few Episodes (FE)
Number of subjects: 1013
Study 616117791 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion drop containing phosphatidylethanolamine (PE) (Systane Balance, Alcon)
Number of subjects: 10
Study 616117791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal spray containing phosphatidylcholine (PC) (Tears again, BioRevive)
Number of subjects: 10
Study 616117791 — intervention group
Group type: COMPARATOR
Intervention: Control saline drop
Number of subjects: 10
Study 616117791 — intervention group
Group type: COMPARATOR
Intervention: Control saline spray
Number of subjects: 10
Study 35399839 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality care intervention for 12 weeks
Number of subjects: 74
Study 35399839 — intervention group
Group type: COMPARATOR
Intervention: Routine care intervention
Number of subjects: 74
Study 32216042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplant (HSCT)
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-only group
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: Age ≤ 3 years old and hyperleukocytosis
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: MLL-rearrangement
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: FLT3-ITD
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: Hyperleukocytosis
Number of subjects: 132
Study 32216042 — intervention group
Group type: COMPARATOR
Intervention: BM blast ≥ 70%
Number of subjects: 132
Study 35451536 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (125µg/day or 5,000 IU/day)
Number of subjects: 55
Study 35451536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 34367654 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (3-7 repetitions of 3 min at 100% of VO2peak interspersed by 1.5 min at 50% of VO2peak)
Number of subjects: 44
Study 34367654 — intervention group
Group type: COMPARATOR
Intervention: MICT (60% of maximal oxygen peak, VO2peak)
Number of subjects: 44
Study 36065795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazides
Number of subjects: 513
Study 36065795 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood urea concentration
Number of subjects: 513
Study 36065795 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 513
Study 32438600 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered intervention over a 10-week period comprising 10 modules addressing behavior change techniques associated with physical activity.
Number of subjects: 80
Study 35440017 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage
Number of subjects: 2008
Study 35440017 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate beverages
Number of subjects: 2008
Study 32720189 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month one-to-one volunteer mentoring program
Number of subjects: 246
Study 32720189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 246
Study 33223272 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (specifics not provided)
Number of subjects: 0
Study 33223272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35351535 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg/day for 24 weeks
Number of subjects: 80
Study 35351535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32192073 — intervention group
Group type: EXPERIMENTAL
Intervention: FES Rowing with stimulation of vasti and soleus during drive and tibialis anterior during recovery
Number of subjects: 20
Study 32606055 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPS+ intervention
Number of subjects: 526
Study 32606055 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 526
Study 35176971 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week music running program with a musical beat 7.5-10% higher than mean cadence
Number of subjects: 5
Study 35176971 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline period)
Number of subjects: 5
Study 35176971 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week music running program
Number of subjects: 5
Study 33590487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools of the Mind prekindergarten curriculum
Number of subjects: 60
Study 33590487 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control condition
Number of subjects: 60
Study 32432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with higher total motile sperm count (TMC)
Number of subjects: 854
Study 32432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with lower total motile sperm count (TMC)
Number of subjects: 854
Study 32432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with patient discomfort
Number of subjects: 854
Study 32432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with timing from hCG injection
Number of subjects: 854
Study 35372576 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Directed Thrombolysis (CDT)
Number of subjects: 74
Study 35372576 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Intravenous Thrombolysis (PIT)
Number of subjects: 74
Study 35372576 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT
Number of subjects: 74
Study 35372576 — intervention group
Group type: COMPARATOR
Intervention: PIT
Number of subjects: 74
Study 34528282 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg PMO once daily
Number of subjects: 30
Study 34528282 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg PMO twice daily
Number of subjects: 30
Study 34528282 — intervention group
Group type: EXPERIMENTAL
Intervention: 540 mg PMO thrice daily
Number of subjects: 30
Study 32635883 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 100
Study 32635883 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100
Study 33964572 — intervention group
Group type: EXPERIMENTAL
Intervention: ALP 250 mg + EVE 2.5 mg
Number of subjects: 10
Study 33964572 — intervention group
Group type: EXPERIMENTAL
Intervention: ALP 200 mg + EVE 2.5 mg + EXE 25 mg
Number of subjects: 10
Study 33832878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) plus Best Supportive Care (BSC)
Number of subjects: 0
Study 33832878 — intervention group
Group type: COMPARATOR
Intervention: Ramucirumab (8 mg/kg) plus erlotinib (25 mg/day)
Number of subjects: 0
Study 35384736 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Centered Lifestyle Intervention (FCLI) - six registered dietitian-led sessions focusing on physical activity, nutrition education, and behavioral counseling.
Number of subjects: 60
Study 35384736 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) - no intervention.
Number of subjects: 60
Study 35384736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FCLI and CTRL).
Number of subjects: 60
Study 33811392 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Validation (n = 311)
Number of subjects: 622
Study 33811392 — intervention group
Group type: COMPARATOR
Intervention: Cross-Validation (n = 311)
Number of subjects: 622
Study 35430440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (200 ppb)
Number of subjects: 32
Study 35430440 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 32
Study 32638373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine treatment
Number of subjects: 189
Study 32638373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-based polychemotherapy
Number of subjects: 189
Study 32638373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine as a single agent
Number of subjects: 189
Study 32638373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine combined with other chemotherapeutics (oxaliplatin and vincristine)
Number of subjects: 189
Study 32629668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoids + methotrexate + hydroxychloroquine
Number of subjects: 80
Study 32629668 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate + hydroxychloroquine
Number of subjects: 80
Study 35869733 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline with 5% eucalyptus
Number of subjects: 120
Study 35869733 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 120
Study 34187541 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block (SCPB) with 0.2% ropivacaine, 15mL
Number of subjects: 136
Study 34187541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 136
Study 34187541 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block (SCPB)
Number of subjects: 136
Study 35725261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led volunteer support
Number of subjects: 0
Study 35725261 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-driven pain assessment
Number of subjects: 0
Study 35725261 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nurse-led volunteer support and technology-driven pain assessment
Number of subjects: 0
Study 35725261 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision corticotomy (PCG)
Number of subjects: 26
Study 33378476 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study 33983564 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% capsaicin cutaneous patch
Number of subjects: 12
Study 34097048 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated behavioral intervention (2 emails/week with feedback and tips, 1 letter/month with peer comparisons and financial incentives)
Number of subjects: 602
Study 34097048 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated behavioral intervention
Number of subjects: 602
Study 34097048 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 letter/month with general healthy lifestyle information)
Number of subjects: 602
Study 34097048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 602
Study 33528318 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 1125
Study 36429745 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-SD intervention
Number of subjects: 445
Study 33826656 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (doses ranging from 500-1500mg)
Number of subjects: 0
Study 33826656 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically based pharmacokinetic (PBPK) model for metformin in humans
Number of subjects: 0
Study 33826656 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPK model for metformin in mice
Number of subjects: 0
Study 32034074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocapuldencel-T plus standard of care (SOC)
Number of subjects: 462
Study 32034074 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 462
Study 35248916 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% body weight load
Number of subjects: 30
Study 35248916 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% body weight load
Number of subjects: 30
Study 35248916 — intervention group
Group type: COMPARATOR
Intervention: 0% body weight load (control group)
Number of subjects: 30
Study 33115543 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg orally daily for 14 days)
Number of subjects: 204
Study 33115543 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Best Conventional Care (BCC)
Number of subjects: 204
Study 33115543 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 204
Study 33115543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 36189751 — intervention group
Group type: EXPERIMENTAL
Intervention: IV push administration of levetiracetam
Number of subjects: 137
Study 36189751 — intervention group
Group type: COMPARATOR
Intervention: IV piggyback administration of levetiracetam
Number of subjects: 137
Study 33733520 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Number of subjects: 424
Study 33733520 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) tools
Number of subjects: 424
Study 34902262 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus a single subcutaneous dose of sarilumab 400 mg
Number of subjects: 115
Study 34902262 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus a single subcutaneous dose of sarilumab 200 mg
Number of subjects: 115
Study 34902262 — intervention group
Group type: COMPARATOR
Intervention: SOC (control group)
Number of subjects: 115
Study 32393092 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter Yoga (LY)
Number of subjects: 35
Study 32393092 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Breathing
Number of subjects: 35
Study 32393092 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 33380581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich gas (HG) inhalation during a 60-minute recovery phase after exercise
Number of subjects: 8
Study 33380581 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation (ambient air) during a 60-minute recovery phase after exercise
Number of subjects: 8
Study 34928519 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml thin liquid bolus
Number of subjects: 19
Study 34928519 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml thin liquid bolus
Number of subjects: 19
Study 34928519 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml thin liquid bolus
Number of subjects: 19
Study 34928519 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml thick liquid bolus
Number of subjects: 19
Study 34928519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-swallow UES basal pressure
Number of subjects: 19
Study 34928519 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-swallow UES contractile integral
Number of subjects: 19
Study 32312337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (containing at least 250 mg DHA and at least 60 mg EPA)
Number of subjects: 420
Study 32312337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 420
Study 35043869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral erector spinae plane block combined with intravenous patient-controlled analgesia (iv PCA)
Number of subjects: 50
Study 35043869 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (iv PCA) alone
Number of subjects: 50
Study 34096642 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing information on public benefits of bed net use and others' bed net use
Number of subjects: 0
Study 32214333 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic chart review
Number of subjects: 78
Study 32214333 — intervention group
Group type: COMPARATOR
Intervention: Paper chart review
Number of subjects: 78
Study 35876440 — intervention group
Group type: EXPERIMENTAL
Intervention: MedLift (Prostatic Urethral Lift)
Number of subjects: 187
Study 35876440 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 187
Study 35876440 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 187
Study 33975490 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 47
Study 33975490 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 47